MedTrace Logo

Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

NCT05490485 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-11-08

No results posted yet for this study

Summary

This study is a card Rayleigh bead single combined cisplatin treatment of advanced squamous cell carcinoma of the skin resistance of single arm phase II study, open, single center, plan in two years into the group of 20 cases with histologic diagnosis of lymph node metastasis or distant metastasis CSCC of (1) or surgery can't/couldn't thorough radiotherapy, CSCC of locally advanced (class 2), To evaluate the efficacy of camrelizumab (PD-1 mab) combined with cisplatin in the treatment of advanced CSCC.

Conditions

  • Squamous Cell Carcinoma of the Skin

Interventions

DRUG

Camrelizumab

Camrelizumab combined with cisplatin for advanced cutaneous squamous cell carcinoma

Sponsors & Collaborators

  • Henan Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-05
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05490485 on ClinicalTrials.gov